Skip to main content

Amgen stock price and financials

  • AMGN · Nasdaq
  • Biotechnology
  • S&P 500
$465.67−0.30%Close 13 Nov 2026
Market value
$253.8B
P/E
27.03
EV / EBITDA
17.12
Dividend yield
2.1%
Beta · 1 year
0.49
Return · 1 year
+38.5%
52-week range$312.39 — $483.99

Share price close 16 Nov 2026

+7.8%1 monthHigh $478.48Low $424.94
$420$440$460$480Q3 FY2026 report filed 4 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+43.4%6 monthsHigh $478.48Low $324.39
$300$350$400$450$500Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+43.0%year to dateHigh $478.48Low $320.72
$300$350$400$450$500Q4 FY2025 report filed 13 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+39.0%1 yearHigh $478.48Low $313.85
$300$350$400$450$500Q4 FY2025 report filed 13 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+71.4%3 yearsHigh $478.48Low $258.59
$200$300$400$500Q4 FY2023 report filed 14 Feb 2024Q1 FY2024 report filed 3 May 2024Q2 FY2024 report filed 7 Aug 2024Q3 FY2024 report filed 31 Oct 2024Q4 FY2024 report filed 14 Feb 2025Q1 FY2025 report filed 2 May 2025Q2 FY2025 report filed 6 Aug 2025Q3 FY2025 report filed 5 Nov 2025Q4 FY2025 report filed 13 Feb 2026Q1 FY2026 report filed 1 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 4 Nov 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+222%10 yearsHigh $478.48Low $143.45
$100$200$300$400$500Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

Amgen reported revenue of $36.8 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 10.0% from fiscal 2024. Net income was $7.71 billion and diluted earnings per share $14.23.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $10.4 billion, up 8.5% from a year earlier.

Figures from Amgen's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 4 Nov 2026.

Against Health Care

Growth
Upper half
Revenue +7.6% a year over five years · 19th of 37
Profitability
Upper half
Return on invested capital 13.7%, five-year average · 13th of 38
Balance sheet
Lower half
Net debt 2.4× EBITDA · 23rd of 38
Valuation
Below the median
P/E 27.0 · 15th of 36

Among the sector's S&P 500 members with the figure; the longer the bar, the better placed. Debt and P/E rank lower first.

Revenue FY2025
$36.75B+10.0%
Net income
$7.71B+88.5%
Diluted EPS
$14.23+88.2%
Gross margin
67.2%+5.7 pts
Free cash flow
$8.10B−22.1%
Net debt
$46.31B−5.3%

Fiscal 2025 against fiscal 2024; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2016–2025

  • Revenue
  • Net income
$0$10B$20B$30B$40BRevenue, FY16: $22.99BNet income, FY16: $7.72BFY16Revenue, FY17: $22.85BNet income, FY17: $1.98BFY17Revenue, FY18: $23.75BNet income, FY18: $8.39BFY18Revenue, FY19: $23.36BNet income, FY19: $7.84BFY19Revenue, FY20: $25.42BNet income, FY20: $7.26BFY20Revenue, FY21: $25.98BNet income, FY21: $5.89BFY21Revenue, FY22: $26.32BNet income, FY22: $6.55BFY22Revenue, FY23: $28.19BNet income, FY23: $6.72BFY23Revenue, FY24: $33.42BNet income, FY24: $4.09BFY24Revenue, FY25: $36.75BNet income, FY25: $7.71BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 4 Nov 2026 · Full results →

Revenue
$10.37B+8.5% on a year
Gross margin
73.1%+5.4 pts on a year
Operating income
$3.71B+46.9% on a year
Net income
$3.86B+20.1% on a year
Diluted EPS
$7.08+19.4% on a year
Free cash flow
$3.65B−14.0% on a year

Comparable companies All of Health Care →

Amgen beside the other S&P 500 members in Biotechnology, by market value.

Amgen and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
Gilead SciencesGILD$210.2B+0.1%+36.2%+6.5%−12.5%—
BiogenBIIB$37.52B+1.2%+56.9%+2.3%3.4%108.0
IncyteINCY$24.67B−0.6%+11.7%+24.9%6.7%61.2
ModernaMRNA—−3.4%+736%———
Regeneron PharmaceuticalsREGN—+0.4%+40.2%———

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2016–2025

  • Gross
  • Operating
  • Net
0%50%100%67.2%24.7%21.0%FY16FY19FY22FY25

Amgen revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By product

Amgen revenue by product, by fiscal year
RevenueFY 2023FY 2024FY 2025
Product sales$26.91B$32.03B+19.0%$35.15B+9.7%
Other revenues$1.28B$1.40B+9.2%$1.60B+14.7%
Total revenue$28.19B$33.42B$36.75B

By region

Amgen revenue by region, by fiscal year
RevenueFY 2021FY 2022FY 2023FY 2024FY 2025
United States$18.19B$18.59B+2.2%$19.81B+6.5%$23.86B+20.5%$26.42B+10.7%
ROW$7.79B$7.73B−0.7%$8.38B+8.5%$9.56B+14.0%$10.33B+8.1%
Total revenue$25.98B$26.32B$28.19B$33.42B$36.75B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Amgen income statement, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Revenue$22.99B$22.85B$23.75B$23.36B$25.42B$25.98B$26.32B$28.19B$33.42B$36.75B
Revenue growth+6.1%−0.6%+3.9%−1.6%+8.8%+2.2%+1.3%+7.1%+18.6%+10.0%
Gross profit$18.83B$18.78B$19.65B$19.01B$19.27B$19.52B$19.92B$19.74B$20.57B$24.71B
Operating income$9.79B$9.97B$10.26B$9.67B$9.14B$7.64B$9.57B$7.90B$7.26B$9.08B
Net income$7.72B$1.98B$8.39B$7.84B$7.26B$5.89B$6.55B$6.72B$4.09B$7.71B
Diluted EPS$10.24$2.69$12.62$12.88$12.31$10.28$12.11$12.49$7.56$14.23
Gross margin81.9%82.2%82.7%81.4%75.8%75.2%75.7%70.0%61.5%67.2%
Operating margin42.6%43.6%43.2%41.4%35.9%29.4%36.3%28.0%21.7%24.7%
Net margin33.6%8.7%35.3%33.6%28.6%22.7%24.9%23.8%12.2%21.0%

Cash flow

Amgen cash flow, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Operating cash flow$10.35B$11.18B$11.30B$9.15B$10.50B$9.26B$9.72B$8.47B$11.49B$9.96B
Capital expenditure$738.0M$664.0M$738.0M$618.0M$608.0M$880.0M$936.0M$1.11B$1.10B$1.86B
Free cash flow$9.62B$10.51B$10.56B$8.53B$9.89B$8.38B$8.79B$7.36B$10.39B$8.10B

Balance sheet and shares

Amgen balance sheet and shares, annual
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Cash and equivalents$3.24B$3.80B$6.95B$6.04B$6.27B$7.99B$7.63B$10.94B$11.97B$9.13B
Total debt$34.60B$35.34B$33.93B$30.43B$33.45B$33.98B$39.64B$65.42B$60.88B$55.44B
Shareholders' equity$29.88B$25.24B$12.50B$9.67B$9.41B$6.70B$3.66B$6.23B$5.88B$8.66B
Diluted shares754M735M665M609M590M573M541M538M541M542M
Dividends per share$4.15$4.77$5.41$5.95$6.56$7.22$7.95$8.64$9.13$9.66

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Amgen quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$9.09B$8.15B$9.18B$9.56B$9.87B$8.62B$10.05B$10.37B
Revenue, year on year+10.9%+9.4%+9.4%+12.4%+8.6%+5.8%+9.5%+8.5%
Gross margin65.7%63.6%67.2%67.8%69.8%68.2%72.0%73.1%
Operating income$2.31B$1.18B$2.66B$2.53B$2.72B$2.67B$3.51B$3.71B
Net income$627.0M$1.73B$1.43B$3.22B$1.33B$1.82B$2.38B$3.86B
Diluted EPS$1.16$3.20$2.65$5.93$2.46$3.34$4.37$7.08
Free cash flow$4.40B$980.0M$1.91B$4.25B$961.0M$1.48B$3.49B$3.65B

Operating KPIs

The operating figures Amgen reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Amgen operating KPIs
KPILatestPeriodChange on a yearRecent periods
Product sales$9.9Bquarter to 30 Sep 2026up 8.2%
Repatha revenue$1.1Bquarter to 30 Sep 2026up 36.6%
EVENITY revenue$751.0Mquarter to 30 Sep 2026up 38.8%
Prolia revenue$632.0Mquarter to 30 Sep 2026down 44.5%
ENBREL revenue$611.0Mquarter to 30 Sep 2026up 5.3%
TEZSPIRE revenue$538.0Mquarter to 30 Sep 2026up 42.7%
TEPEZZA revenue$526.0Mquarter to 30 Sep 2026down 6.1%
BLINCYTO revenue$496.0Mquarter to 30 Sep 2026up 26.5%
Otezla revenue$481.0Mquarter to 30 Sep 2026down 17.8%
Nplate revenue$472.0Mquarter to 30 Sep 2026up 3.3%
UPLIZNA revenue$451.0Mquarter to 30 Sep 2026up 191.0%
KRYSTEXXA revenue$419.0Mquarter to 30 Sep 2026up 30.9%
IMDELLTRA/IMDYLLTRA revenue$406.0Mquarter to 30 Sep 2026up 128.1%
Vectibix revenue$335.0Mquarter to 30 Sep 2026up 18.0%
KYPROLIS revenue$330.0Mquarter to 30 Sep 2026down 8.1%
Aranesp revenue$329.0Mquarter to 30 Sep 2026down 7.8%
XGEVA revenue$288.0Mquarter to 30 Sep 2026down 46.6%
United States revenue$26.4Bfiscal year to 31 Dec 2025up 10.7%
ROW revenue$10.3Bfiscal year to 31 Dec 2025up 8.1%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Amgen's revenue in fiscal 2025?

$36.8 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Amgen's net income in fiscal 2025?

$7.71 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Amgen's diluted earnings per share in fiscal 2025?

$14.23 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Amgen's gross margin?

67.2% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Amgen's operating margin?

24.7% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Amgen generate in fiscal 2025?

$8.10 billion for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Amgen's revenue come from?

In fiscal 2025, by product: Product sales $35.15B (96%), Other revenues $1.60B (4.4%), out of $36.75B in all, as stated in its annual report.

In the terminal

Twenty years of Amgen's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans